The aim of this retrospective study was to determine the rate of metastases in the central neck compartment and examine the morbidity and rate of recurrence in patients with differentiated thyroid cancer treated with or without a central neck dissection. Two hundred and fifteen patients undergoing total thyroidectomy with preoperative diagnosis of differentiated thyroid cancer, in the absence of suspicious nodes, were divided in two groups: those who underwent a thyroidectomy only (group A; ) and those who also received a central neck dissection (group B; ). Five cases (2.32%) of nodal recurrence were observed: 3 in group A and 2 in group B. Tumor histology was associated with a risk of recurrence: Hürthle cell-variant and tall cell-variant carcinomas were associated with a high risk of recurrence. Multifocality and extrathyroidal invasion also presented a higher risk, while smaller tumors were at lower risk. The results of this study suggest that prophylactic central neck dissection should be reserved for high-risk patients only. A wider use of immunocytochemical and genetic markers to improve preoperative diagnosis and the development of methods for the intraoperative identification of metastatic lymph nodes will be useful in the future for the improved selection of patients for central neck dissections. 1. Introduction Differentiated thyroid carcinoma (particularly papillary) is the most common thyroid malignancy, comprising approximately 90% of new cases of thyroid cancer in iodine-sufficient areas of the world [1–3]. The prognosis of treated differentiated thyroid cancer is generally excellent, with 10-year overall survival rates exceeding 90% [1, 2, 4]. Total thyroidectomy is generally accepted as the procedure of choice for all papillary thyroid carcinomas exceeding 10？mm in diameter [1, 2]. Lymph node metastases are common in papillary thyroid carcinoma, occurring in 20–50% of patients, as identified using standard pathological techniques [1, 2, 5–10]. Micrometastases are even more common and may be found in 90% of patients [5–7, 10]. The central compartment of the neck, also known as level VI, is the most frequently involved [1, 2, 5, 8, 11–13]. Regional lymph node involvement is associated with increased tumor recurrence [2, 5, 7, 14], and recurrence rates are higher in node positive patients over the age of 45 years [5]. When neither imaging nor palpation of the lymph nodes arouses the suspicion of metastatic disease, the value of prophylactic central neck dissection becomes a matter of debate [2, 15]. It has traditionally been accepted that
References
[1]
R. Alvarado, M. S. Sywak, L. Delbridge, and S. B. Sidhu, “Central lymph node dissection as a secondary procedure for papillary thyroid cancer: is there added morbidity?” Surgery, vol. 145, no. 5, pp. 514–518, 2009.
[2]
M. Barczyński, A. Konturek, M. Stopa, and W. Nowak, “Prophylactic central neck dissection for papillary thyroid cancer,” British Journal of Surgery, vol. 100, no. 3, pp. 410–418, 2013.
[3]
P. G. Calò, M. L. Lai, E. Guaitoli et al., “Difficulties in the diagnosis of thyroid paraganglioma: a clinical case,” La Clinica Terapeutica, vol. 164, pp. e35–e39, 2013.
[4]
E. Baldini, S. Sorrenti, A. Catania et al., “Diagnostic utility of thyroglobulin measurement in the fine needle aspirates from cervical lymph nodes: a case report,” Il Giornale di Chirurgia, vol. 33, no. 11-12, pp. 387–391, 2012.
[5]
E. J. Chisholm, E. Kulinskaya, and N. S. Tolley, “Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone,” Laryngoscope, vol. 119, no. 6, pp. 1135–1139, 2009.
[6]
G. Conzo, D. Pasquali, G. Bellastella et al., “Total thyroidectomy, without prophylactic central lymph node dissection, in the treatment of differentiated thyroid cancer. Clinical retrospective study on 221 cases,” Endocrine, 2013.
[7]
E. L. Mazzaferri, G. M. Doherty, and D. L. Steward, “The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma,” Thyroid, vol. 19, no. 7, pp. 683–689, 2009.
[8]
M. Sywak, L. Cornford, P. Roach, P. Stalberg, S. Sidhu, and L. Delbridge, “Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer,” Surgery, vol. 140, no. 6, pp. 1000–1007, 2006.
[9]
M. L. White and G. M. Doherty, “Level VI lymph node dissection for papillary thyroid cancer,” Minerva Chirurgica, vol. 62, no. 5, pp. 383–393, 2007.
[10]
M. L. White, P. G. Gauger, and G. M. Doherty, “Central lymph node dissection in differentiated thyroid cancer,” World Journal of Surgery, vol. 31, no. 5, pp. 895–904, 2007.
[11]
M. A. Rosenbaum and C. R. McHenry, “Central neck dissection for papillary thyroid cancer,” Archives of Otolaryngology, vol. 135, no. 11, pp. 1092–1097, 2009.
[12]
C. X. Shan, W. Zhang, D. Z. Jiang, X. M. Zheng, S. Liu, and M. Qiu, “Routine central neck dissection in differentiated thyroid carcinoma: a systematic review and meta-analysis,” Laryngoscope, vol. 122, no. 4, pp. 797–804, 2012.
[13]
W. T. Shen, L. Ogawa, D. Ruan et al., “Central neck lymph node dissection for papillary thyroid cancer: comparison of complication and recurrence rates in 295 initial dissections and reoperations,” Archives of Surgery, vol. 145, no. 3, pp. 272–275, 2010.
[14]
J. A. Pereira, J. Jimeno, J. Miquel et al., “Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma,” Surgery, vol. 138, no. 6, pp. 1095–1101, 2005.
[15]
D. Giordano, R. Valcavi, G. B. Thompson et al., “Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature,” Thyroid, vol. 22, no. 9, pp. 911–917, 2012.
[16]
T. Carling, W. D. Long III, and R. Udelsman, “Controversy surrounding the role for routine central lymph node dissection for differentiated thyroid cancer,” Current Opinion in Oncology, vol. 22, no. 1, pp. 30–34, 2010.
[17]
Y. S. Lee, S. W. Kim, S. W. Kim et al., “Extent of routine central lymph node dissection with small papillary thyroid carcinoma,” World Journal of Surgery, vol. 31, no. 10, pp. 1954–1959, 2007.
[18]
E. Baldini, S. Sorrenti, C. Di Gioia et al., “Cervical lymph node metastases from thyroid cancer: does thyroglobulin and calcitonin measurement in fine needle aspirates improve the diagnostic value of cytology?” BMC Clin Pathol, vol. 13, article 7, 2013.
[19]
F. Boi, G. Baghino, F. Atzeni, M. L. Lai, G. Faa, and S. Mariotti, “The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 4, pp. 1364–1369, 2006.
[20]
L. Falvo, A. Catania, V. D'Andrea, A. Marzullo, M. C. Giustiniani, and E. De Antoni, “Prognostic importance of histologic vascular invasion in papillary thyroid carcinoma,” Annals of Surgery, vol. 241, no. 4, pp. 640–646, 2005.
[21]
C. I. Lundgren, P. Hall, P. W. Dickman, and J. Zedenius, “Clinically significant prognostic factors for differentiated thyroid carcinoma: a populationed-based, nested case-control study,” Cancer, vol. 106, no. 3, pp. 524–531, 2006.
[22]
J. L. Roh, J. M. Kim, and C. I. Park, “Central cervical nodal metastasis from papillary thyroid microcarcinoma: pattern and factors predictive of nodal metastasis,” Annals of Surgical Oncology, vol. 15, no. 9, pp. 2482–2486, 2008.
[23]
Y. Ito, C. Tomoda, T. Uruno et al., “Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid,” World Journal of Surgery, vol. 30, no. 1, pp. 91–99, 2006.
[24]
B. M. Sadowski, S. K. Snyder, and T. C. Lairmore, “Routine bilateral central lymph node clearance for papillary thyroid cancer,” Surgery, vol. 146, no. 4, pp. 696–705, 2009.
[25]
M. Shindo, J. C. Wu, E. E. Park, and F. Tanzella, “The importance of central compartment elective lymph node excision in the staging and treatment of papillary thyroid cancer,” Archives of Otolaryngology, vol. 132, no. 6, pp. 650–654, 2006.
[26]
P. G. Calò, G. Pisano, F. Medas, A. Tatti, M. Tuveri, and A. Nicolosi, “Risk factors in reoperative thyroid surgery for recurrent goitre: our experience,” Il Giornale di Chirurgia, vol. 33, pp. 335–338, 2012.
[27]
P. G. Calò, G. Pisano, G. Piga et al., “Postoperative hematomas after thyroid surgery: incidence and risk factors in our experience,” Annali Italiani di Chirurgia, vol. 81, no. 5, pp. 343–347, 2010.
[28]
P. G. Calò, G. Pisano, F. Medas et al., “Intraoperative recurrent laryngeal nerve monitoring in thyroid surgery: is it really useful?” La Clinica Terapeutica, vol. 164, pp. e193–e198, 2013.
[29]
N. Palestini, A. Borasi, L. Cestino, M. Freddi, C. Odasso, and A. Robecchi, “Is central neck dissection a safe procedure in the treatment of papillary thyroid cancer? Our experience,” Langenbeck's Archives of Surgery, vol. 393, no. 5, pp. 693–698, 2008.
[30]
Y. I. Son, H. S. Jeong, C. H. Baek et al., “Extent of prophylactic lymph node dissection in the central neck area of the patients with papillary thyroid carcinoma: comparison of limited versus comprehensive lymph node dissection in a 2-year safety study,” Annals of Surgical Oncology, vol. 15, no. 7, pp. 2020–2026, 2008.
[31]
P. G. Calò, G. Pisano, F. Medas, A. Tatti, M. Tuveri, and A. Nicolosi, “The use of the harmonic scalpel in thyroid surgery. Our experience,” Annali Italiani di Chirurgia, vol. 83, pp. 7–12, 2012.
[32]
R. Cirocchi, C. Boselli, S. Guarino et al., “Total thyroidectomy with ultrasonic dissector for cancer: multicentric experience,” World Journal of Surgical Oncology, vol. 10, article 70, 2012.
[33]
M. K. Kim, S. H. Mandel, Z. Baloch et al., “Morbidity following central compartment reoperation for recurrent or persistent thyroid cancer,” Archives of Otolaryngology, vol. 130, no. 10, pp. 1214–1216, 2004.
[34]
A. Machens, H. J. Holzhausen, and H. Dralle, “Skip metastases in thyroid cancer leaping the central lymph node compartment,” Archives of Surgery, vol. 139, no. 1, pp. 43–45, 2004.
[35]
F. Sorrentino, J. Atzeni, G. Romano, G. Buscemi, and M. Romano, “Differentiated microcarcinoma of the thyroid gland,” Il Giornale di Chirurgia, vol. 31, no. 6-7, pp. 277–278, 2010.
[36]
P. Caria, T. Dettori, D. V. Frau et al., “Assessing RET/PTC in thyroid nodule fine-needle aspirates: the FISH point of view,” Endocrine-Related Cancer, vol. 20, pp. 527–536, 2013.
